Document is current
Any future updates will be listed below
-
Authors
Lee, Dong-Young https://orcid.org/0000-0003-4963-8286
Chung, Yerin https://orcid.org/0009-0008-1094-0967
Kim, Beom
Lee, Jae-Hon https://orcid.org/0000-0002-9490-2050
Lee, Kangbaek https://orcid.org/0000-0001-6601-1368
Lee, Young https://orcid.org/0000-0003-0178-0187
Lee, Yu Ho https://orcid.org/0000-0001-5231-0551
Ahn, Shin Young https://orcid.org/0000-0002-6844-0614
Kim, Yang Gyun https://orcid.org/0000-0002-3497-5514
Hwang, Hyeon Seok https://orcid.org/0000-0002-6356-4933
Moon, Ju-Young https://orcid.org/0000-0003-3244-8371
Ryoo, Jae-Hong https://orcid.org/0000-0002-5232-1426
Teopiz, Kayla M. https://orcid.org/0000-0001-8429-6563
McIntyre, Roger S. https://orcid.org/0000-0003-4733-2523
-
Funding
Funding for this research was provided by:
Veterans Health Service Medical Center Research Grant (VHSMC23035)
- License Information
-
More Information
Article History
Received: 11 January 2024
Accepted: 5 April 2024
First Online: 15 June 2024
Declarations
:
: Roger S. McIntyre has received research grant support from CIHR/GACD/National Natural Science Foundation of China (NSFC) and the Milken Institute; speaker/consultation fees from Lundbeck, Janssen, Alkermes, Neumora Therapeutics, Boehringer Ingelheim, Sage, Biogen, Mitsubishi Tanabe, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, Sunovion, Bausch Health, Axsome, Novo Nordisk, Kris, Sanofi, Eisai, Intra-Cellular, NewBridge Pharmaceuticals,Viatris, Abbvie, Atai Life Sciences. Dr. Roger McIntyre is a CEO of Braxia Scientific Corp. Kayla M. Teopiz has received fees from Braxia Scientific Corp. The rest of authors have declared no competing interests.
: All procedures used adhere to the tenets of the Declaration of Helsinki. Written informed consents were obtained from all participants.
